Cargando…
Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700280/ https://www.ncbi.nlm.nih.gov/pubmed/34953523 http://dx.doi.org/10.1016/S1470-2045(21)00715-4 |
| _version_ | 1784620719192145920 |
|---|---|
| author | Ligumsky, Hagai Dor, Herut Etan, Tal Golomb, Inbal Nikolaevski-Berlin, Alla Greenberg, Inbal Halperin, Tamar Angel, Yoel Henig, Oryan Spitzer, Avishay Slobodkin, Marina Wolf, Ido |
| author_facet | Ligumsky, Hagai Dor, Herut Etan, Tal Golomb, Inbal Nikolaevski-Berlin, Alla Greenberg, Inbal Halperin, Tamar Angel, Yoel Henig, Oryan Spitzer, Avishay Slobodkin, Marina Wolf, Ido |
| author_sort | Ligumsky, Hagai |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8700280 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87002802021-12-28 Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer Ligumsky, Hagai Dor, Herut Etan, Tal Golomb, Inbal Nikolaevski-Berlin, Alla Greenberg, Inbal Halperin, Tamar Angel, Yoel Henig, Oryan Spitzer, Avishay Slobodkin, Marina Wolf, Ido Lancet Oncol Comment Elsevier Ltd. 2022-02 2021-12-23 /pmc/articles/PMC8700280/ /pubmed/34953523 http://dx.doi.org/10.1016/S1470-2045(21)00715-4 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Ligumsky, Hagai Dor, Herut Etan, Tal Golomb, Inbal Nikolaevski-Berlin, Alla Greenberg, Inbal Halperin, Tamar Angel, Yoel Henig, Oryan Spitzer, Avishay Slobodkin, Marina Wolf, Ido Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer |
| title | Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer |
| title_full | Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer |
| title_fullStr | Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer |
| title_full_unstemmed | Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer |
| title_short | Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer |
| title_sort | immunogenicity and safety of bnt162b2 mrna vaccine booster in actively treated patients with cancer |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700280/ https://www.ncbi.nlm.nih.gov/pubmed/34953523 http://dx.doi.org/10.1016/S1470-2045(21)00715-4 |
| work_keys_str_mv | AT ligumskyhagai immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT dorherut immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT etantal immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT golombinbal immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT nikolaevskiberlinalla immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT greenberginbal immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT halperintamar immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT angelyoel immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT henigoryan immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT spitzeravishay immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT slobodkinmarina immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT wolfido immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer AT immunogenicityandsafetyofbnt162b2mrnavaccineboosterinactivelytreatedpatientswithcancer |